Literature DB >> 30589478

Response to FDA Commissioner's statement on Dsuvia approval.

Michael H Bernstein1, Francesca L Beaudoin2, Molly Magill1.   

Abstract

Entities:  

Keywords:  Dsuvia; Sufentanil; medication; opioid; opioid crisis; prescription opioid

Year:  2019        PMID： 30589478      PMCID： PMC6411435          DOI： 10.1111/add.14539

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   6.526


× No keyword cloud information.
  3 in total

Review 1.  Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations.

Authors:  Robert H Dworkin; Dennis C Turk; Michael P McDermott; Sarah Peirce-Sandner; Laurie B Burke; Penney Cowan; John T Farrar; Sharon Hertz; Srinivasa N Raja; Bob A Rappaport; Christine Rauschkolb; Cristina Sampaio
Journal:  Pain       Date:  2009-12       Impact factor: 6.961

2.  Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial.

Authors:  Timothy I Melson; David L Boyer; Harold S Minkowitz; Alparslan Turan; Yu-Kun Chiang; Mark A Evashenk; Pamela P Palmer
Journal:  Pain Pract       Date:  2014-08-25       Impact factor: 3.183

3.  Between evidence and commerce - the case of sufentanil sublingual tablet systems.

Authors:  C Bantel; H C Laycock
Journal:  Anaesthesia       Date:  2017-12-08       Impact factor: 6.955
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.